WO2017003194A3 - Neuron-protecting composition containing green tea amino acid and caffeine - Google Patents

Neuron-protecting composition containing green tea amino acid and caffeine Download PDF

Info

Publication number
WO2017003194A3
WO2017003194A3 PCT/KR2016/006990 KR2016006990W WO2017003194A3 WO 2017003194 A3 WO2017003194 A3 WO 2017003194A3 KR 2016006990 W KR2016006990 W KR 2016006990W WO 2017003194 A3 WO2017003194 A3 WO 2017003194A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
green tea
caffeine
neuron
composition containing
Prior art date
Application number
PCT/KR2016/006990
Other languages
French (fr)
Korean (ko)
Other versions
WO2017003194A2 (en
Inventor
홍용덕
이범진
최민식
안지홍
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2017003194A2 publication Critical patent/WO2017003194A2/en
Publication of WO2017003194A3 publication Critical patent/WO2017003194A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Tea And Coffee (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)

Abstract

The present specification relates to a neuron-protecting composition containing green tea amino acid and caffeine as active ingredients, wherein the green tea amino acid comprises theanine and one or more types selected from among γ-aminobutyric acid, arginine and alanine, and the value of AC expressed by formula 1 is 5-150 for the neuron-protecting composition. <Formula 1> AC = (green tea amino acid wt%)/(caffeine wt%)
PCT/KR2016/006990 2015-06-30 2016-06-30 Neuron-protecting composition containing green tea amino acid and caffeine WO2017003194A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150093208A KR20170003056A (en) 2015-06-30 2015-06-30 Composition for protecting neuron comprising green tea amino acid and caffeine
KR10-2015-0093208 2015-06-30

Publications (2)

Publication Number Publication Date
WO2017003194A2 WO2017003194A2 (en) 2017-01-05
WO2017003194A3 true WO2017003194A3 (en) 2017-03-02

Family

ID=57608800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/006990 WO2017003194A2 (en) 2015-06-30 2016-06-30 Neuron-protecting composition containing green tea amino acid and caffeine

Country Status (2)

Country Link
KR (1) KR20170003056A (en)
WO (1) WO2017003194A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100235110B1 (en) * 1997-10-29 1999-12-15 서경배 Tea composition containing green tea leaves and green tea leaves with a high GABA content
WO2004020403A2 (en) * 2002-08-27 2004-03-11 Shell William E A composition and method to augment and sustain neurotransmitter production
KR100945310B1 (en) * 2006-05-24 2010-03-03 장해춘 Lactic acid bacteria separated from kimchi and ?-aminobutyric acid produced thereby
KR101064675B1 (en) * 2008-05-29 2011-09-14 목포대학교산학협력단 Method for increasing GABA content in green tea
KR101354370B1 (en) * 2008-01-29 2014-02-18 주식회사 엘지생활건강 A composition for improving ability of memory or concentration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101385560B1 (en) 2012-01-06 2014-04-15 주식회사 디와이내츄럴 Anti-Stress Composition Comprising D-chiro-inositol or Pinitol As Active Ingredient

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100235110B1 (en) * 1997-10-29 1999-12-15 서경배 Tea composition containing green tea leaves and green tea leaves with a high GABA content
WO2004020403A2 (en) * 2002-08-27 2004-03-11 Shell William E A composition and method to augment and sustain neurotransmitter production
KR100945310B1 (en) * 2006-05-24 2010-03-03 장해춘 Lactic acid bacteria separated from kimchi and ?-aminobutyric acid produced thereby
KR101354370B1 (en) * 2008-01-29 2014-02-18 주식회사 엘지생활건강 A composition for improving ability of memory or concentration
KR101064675B1 (en) * 2008-05-29 2011-09-14 목포대학교산학협력단 Method for increasing GABA content in green tea

Also Published As

Publication number Publication date
KR20170003056A (en) 2017-01-09
WO2017003194A2 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
RU2018135921A (en) STABILIZED VANCOMYCIN COMPOSITIONS
PH12017550099A1 (en) Composition suitable for protecting microorganisms
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
MD20140072A2 (en) New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them
MX2018002986A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
GEP201606555B (en) Compounds and compositions for modulating egfr activity
WO2015028966A3 (en) Amino diacids containing peptide modifiers
WO2012021715A3 (en) Stable formulations of linaclotide
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
NZ714558A (en) Formulation comprising a hypolipidemic agent
WO2014016848A3 (en) Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
MX2011012547A (en) Green tea extracts of improved bioavailability.
PH12016501328A1 (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
WO2019147749A3 (en) Stabilized rsv f proteins and uses thereof
MY196762A (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
CA2899024C (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
SG11201901962QA (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
EP4327880A3 (en) Solid state form of ribociclib succinate
ES2530423A2 (en) Novel solid forms of phosphodiesterase type 5 inhibitors
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
WO2013080140A3 (en) Sunscreen compositions containing a novel preservative system
MX2020005564A (en) Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylis oquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16818227

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16818227

Country of ref document: EP

Kind code of ref document: A2